SEC Tracker
Get the app

Immunome IMNM

Immunome announces Q3 2026 financial results and business updates

Immunome (IMNM) filed an 8-K with the SEC on Nov 9, 2026, 4:05 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. Varegacestat PDUFA target action date of April 28, 2027
  2. IM-1021 Phase 1 trial shows 53% objective response rate in B-NHL patients
  3. Immunome expects cash to fund operations into 2028
  4. IM-1340 IND clearance received with Phase 1 trial expected by year-end

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Immunome files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.